Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses
The Journal of Clinical Endocrinology & Metabolism · 18.09.2023 · 108 (10) · 2676-2685
DOI: 10.1210/clinem/dgad166 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 22.03.2023. Verfasst von Alessa Fischer und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), CH-8091 Zurich, Sw…. Hauptthemen laut MEDLINE: Adrenal Gland Neoplasms, Neoplasms, Second Primary, Paraganglioma, Pheochromocytoma. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, University Medicine Zurich.
Abstract (Originalsprache)
Context
Pheochromocytomas and paragangliomas (PPGLs) with pathogenic mutations in the succinate dehydrogenase subunit B (SDHB) are associated with a high metastatic risk. Somatostatin receptor 2 (SSTR2)–dependent imaging is the most sensitive imaging modality for SDHB-related PPGLs, suggesting that SSTR2 expression is a significant cell surface therapeutic biomarker of such tumors.
Objective
Exploration of the relationship between SSTR2 immunoreactivity and SDHB immunoreactivity, mutational status, and clinical behavior of PPGLs. Evaluation of SSTR-based therapies in metastatic PPGLs.
Methods
Retrospective analysis of a multicenter cohort of PPGLs at 6 specialized Endocrine Tumor Centers in Germany, The Netherlands, and Switzerland. Patients with PPGLs participating in the ENSAT registry were included. Clinical data were extracted from medical records, and immunohistochemistry (IHC) for SDHB and SSTR2 was performed in patients with available tumor tissue. Immunoreactivity of SSTR2 was investigated using Volante scores. The main outcome measure was the association of SSTR2 IHC positivity with genetic and clinical–pathological features of PPGLs.
Results
Of 202 patients with PPGLs, 50% were SSTR2 positive. SSTR2 positivity was significantly associated with SDHB- and SDHx-related PPGLs, with the strongest SSTR2 staining intensity in SDHB-related PPGLs (P = .01). Moreover, SSTR2 expression was significantly associated with metastatic disease independent of SDHB/SDHx mutation status (P < .001). In metastatic PPGLs, the disease control rate with first-line SSTR-based radionuclide therapy was 67% (n = 22, n = 11 SDHx), and with first-line “cold” somatostatin analogs 100% (n = 6, n = 3 SDHx).
Conclusion
SSTR2 expression was independently associated with SDHB/SDHx mutations and metastatic disease. We confirm a high disease control rate of somatostatin receptor–based therapies in metastatic PPGLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), CH-8091 Zurich, Switzerland.
- Department of Pathology and Molecular Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.
- Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, 97080 Würzburg, Germany.
- Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
- Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands.
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
ORCID-Profile: Svenja Nölting
Förderung
- German Research Foundation
- University Medicine Zurich
Zitieren
APA
Fischer, A., Kloos, S., Maccio, U., Friemel, J., Remde, H., Fassnacht, M., Pamporaki, C., Eisenhofer, G., Timmers, H. J. L. M., Robledo, M., Fliedner, S. M. J., Wang, K., Maurer, J., Reul, A., Zitzmann, K., Bechmann, N., Žygienė, G., Richter, S., Hantel, C., …, & Nölting, S. (2023). Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2676-2685. https://doi.org/10.1210/clinem/dgad166
Vancouver
Fischer A, Kloos S, Maccio U, Friemel J, Remde H, Fassnacht M, et al. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2676-2685. doi:10.1210/clinem/dgad166
BibTeX
@article{Fischer2023,
author = {Fischer, Alessa and Kloos, Simon and Maccio, Umberto and Friemel, Juliane and Remde, Hanna and Fassnacht, Martin and Pamporaki, Christina and Eisenhofer, Graeme and Timmers, Henri J L M and Robledo, Mercedes and Fliedner, Stephanie M J and Wang, Katharina and Maurer, Julian and Reul, Astrid and Zitzmann, Kathrin and Bechmann, Nicole and Žygienė, Gintarė and Richter, Susan and Hantel, Constanze and Vetter, Diana and Lehmann, Kuno and Mohr, Hermine and Pellegata, Natalia S and Ullrich, Martin and Pietzsch, Jens and Ziegler, Christian G and Bornstein, Stefan R and Kroiss, Matthias and Reincke, Martin and Pacak, Karel and Grossman, Ashley B and Beuschlein, Felix and Nölting, Svenja},
title = {Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {10},
pages = {2676--2685},
doi = {10.1210/clinem/dgad166}
}
EUVIMED